# Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease

> **NCT00702689** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (actual)

## Conditions studied

- Sclerotic Graft Versus Host Disease
- Imatinib Mesylate

## Interventions

- **DRUG:** Gleevec, STI571(Imatinib Mesylate)

## Key facts

- **NCT ID:** NCT00702689
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-15
- **Primary completion:** 2011-05-18
- **Final completion:** 2020-02-26
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00702689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00702689, "Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00702689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*